ALDX

Business Context and Reporting Period

Company: Aldeyra Therapeutics, Inc. (ALDX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Aldeyra is a clinical-stage biotechnology company developing therapies for immune-mediated and metabolic diseases. Its primary focus is on the RASP (reactive aldehyde species) modulator platform. The company has no approved products and generates no product revenue. Its late-stage pipeline includes reproxalap (for dry eye disease and allergic conjunctivitis) and ADX-2191 (for retinitis pigmentosa).

Key Financial Metrics

Liquidity: As of December 31, 2024, the company held $54.5 million in cash and cash equivalents and $46.6 million in marketable securities. Management believes current resources are sufficient to fund operations into 2027.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by 48.8% to $55.9 million in 2024, primarily driven by a 63.7% increase in R&D expenses.
• R&D Spend Surge: R&D expenses rose by $18.7 million year-over-year. This was due to increased external clinical development costs ($10.1 million increase), drug product manufacturing costs ($8.3 million increase), and personnel costs ($1.2 million increase).
• Cash Position: Cash and cash equivalents decreased by approximately $88.3 million, reflecting the higher operating burn rate and net cash used in investing activities ($44.9 million) primarily for the purchase of marketable securities.
• Debt Restructuring: The Hercules Credit Facility was amended in September 2024 to extend the maturity date to April 1, 2026, and adjust the interest rate to the greater of Prime + 3.10% or 11.10%.

Guidance, Outlook, and Material Events

Regulatory Milestones

• Reproxalap (Dry Eye Disease): On November 18, 2024, the FDA accepted a resubmitted New Drug Application (NDA) for review. The Prescription Drug User Fee Act (PDUFA) decision date is set for April 2, 2025. The resubmission included data from a Phase 3 chamber crossover trial that met its primary endpoint.
• Reproxalap (Allergic Conjunctivitis): The company plans to discuss remaining regulatory requirements with the FDA following positive Phase 3 results (INVIGORATE and INVIGORATE-2 trials).

Strategic Partnership (AbbVie)

• Option Agreement: Aldeyra holds an exclusive option agreement with AbbVie Inc. to collaborate on reproxalap. AbbVie has paid $6.0 million in non-refundable fees ($1.0 million option payment + $5.0 million extension fee).
• Expansion Side Letter: In November 2024, the parties amended the agreement. If AbbVie exercises the option, Aldeyra could receive a $100 million upfront payment (net of fees) and up to $300 million in milestones. Aldeyra would receive 40% of US profits and tiered royalties outside the US.
• Current Status: As of February 28, 2025, AbbVie has not exercised the option. The exercise period is now 10 business days following the FDA decision on the NDA.

Risks and Contingencies

• Capital Requirements: The company requires substantial additional financing to fund commercialization if the AbbVie option is not exercised or if further development is needed. A $75 million "at-the-market" sales agreement with Jefferies was established in August 2024, with no sales made as of year-end.
• Legal Proceedings: A putative securities class action lawsuit (Juliana Paice v. Aldeyra Therapeutics, Inc.) is pending regarding disclosures related to ADX-2191 and reproxalap. The company intends to vigorously defend the suit.
• Deprioritization: In 2024, the company ceased development of ADX-2191 for proliferative vitreoretinopathy and de-prioritized ADX-629 for chronic cough and idiopathic nephrotic syndrome due to regulatory and feasibility challenges.

Key Facts for Investor Verification

• April 2, 2025 PDUFA Date: Verify the FDA's decision on the reproxalap NDA for dry eye disease, which is the primary catalyst for potential revenue and the AbbVie option exercise.
• AbbVie Option Exercise: Monitor whether AbbVie exercises its option within 10 business days of the FDA decision, which would trigger a significant cash inflow ($100 million upfront).
• Cash Runway: Confirm the company's ability to fund operations through 2027 without dilutive equity raises, given the $101.2 million cash balance and $15 million debt obligation.
• Commercialization Plan: If the AbbVie option is not exercised, verify the company's specific plan and capital requirements for building a commercial infrastructure for reproxalap.
• Legal Outcome: Track the status of the securities class action lawsuit, as an unfavorable outcome could result in significant damages or settlement costs.